Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

Genetic Inhibition of CaMKII in Dorsal Striatal Medium Spiny Neurons Reduces Functional Excitatory Synapses and Enhances Intrinsic Excitability

Open access

Abstract

Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) is abundant in striatal medium spiny neurons (MSNs). CaMKII is dynamically regulated by changes in dopamine signaling, as occurs in Parkinson's disease as well as addiction. Although CaMKII has been extensively studied in the hippocampus where it regulates excitatory synaptic transmission, relatively little is known about how it modulates neuronal function in the striatum. Therefore, we examined the impact of selectively overexpressing an EGFP-fused CaMKII inhibitory peptide (EAC3I) in striatal medium spiny neurons (MSNs) using a novel transgenic mouse model. EAC3I-expressing cells exhibited markedly decreased excitatory transmission, indicated by a decrease in the frequency of spontaneous excitatory postsynaptic currents (sEPSCs). This decrease was not accompanied by changes in the probability of release, levels of glutamate at the synapse, or changes in dendritic spine density. CaMKII regulation of the AMPA receptor subunit GluA1 is a major means by which the kinase regulates neuronal function in the hippocampus. We found that the decrease in striatal excitatory transmission seen in the EAC3I mice is mimicked by deletion of GluA1. Further, while CaMKII inhibition decreased excitatory transmission onto MSNs, it increased their intrinsic excitability. These data suggest that CaMKII plays a critical role in setting the excitability rheostat of striatal MSNs by coordinating excitatory synaptic drive and the resulting depolarization response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0045323

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Characterization and in vivo localization/expression of CaMKII inhibitory (EAC3I) peptide in EAC3I mice. (A) Schematic of breeding strategy for production of EAC3I mice. CaMKIIalpha promoter drives expression of tTA which binds to the tetO promoter and drives expression of EAC3I peptide fused to EGFP. (B) (Top) Brain slice of EAC3I under brightfield (left) and EGFP epifluorescence (right). (Bottom) Brain slice of EAC3I as above following 3 weeks of doxycycline feeding (200 mg/kg). Note lack of EAC3I-EGFP expression. (C) Sagittal section of EAC3I mouse brain showing restricted endogenous EAC3I-EGFP expression (green) and nissl stain (red, neuronal marker). Scale bar 500 µm. (D) Coronal image of mosaic expression of endogenous EAC3I-EGFP expression (green) in dorsal lateral striatum with a NeuN stain (blue, neuronal marker). Note little to no expression of EAC3I peptide in cortex. CC = corpus callosum, Scale bar 100 µm. (E) 63× image of unstained EAC3I-EGFP expressing MSN (green = endogenous EGFP signal). Note expression in soma, dendrites and dendritic spines (arrows). Scale bar 10 µm. (F) Images of globus pallidus (GP) (left) and substantia nigra pars reticulata (SNR) (right) showing MSN axon terminals (green) and nissl stain (red). GP and SNR cell somas (red, nissl stain) are devoid of EGFP signal. CP = cerebral peduncle. Scale bars 20 µm. (G) (left) DIC image of patch pipette on a MSN in whole cell mode, (right) epifluorescence image of left panel confirming EAC3I-EGFP expression. Scale bar 20 µm. (H) Overlaid coronal images showing EAC3I-EGFP MSN axon terminal field expression in globus pallidus (left) and substania nigra pars reticulata (right) confirming indirect and direct pathway expression, respectively. Scale bar 0.5 mm.
Figure 1 Characterization and in vivo localization/expression of CaMKII inhibitory (EAC3I) peptide in EAC3I mice. (A) Schematic of breeding strategy for production of EAC3I mice. CaMKIIalpha promoter drives expression of tTA which binds to the tetO promoter and drives expression of EAC3I peptide fused to EGFP. (B) (Top) Brain slice of EAC3I under brightfield (left) and EGFP epifluorescence (right). (Bottom) Brain slice of EAC3I as above following 3 weeks of doxycycline feeding (200 mg/kg). Note lack of EAC3I-EGFP expression. (C) Sagittal section of EAC3I mouse brain showing restricted endogenous EAC3I-EGFP expression (green) and nissl stain (red, neuronal marker). Scale bar 500 µm. (D) Coronal image of mosaic expression of endogenous EAC3I-EGFP expression (green) in dorsal lateral striatum with a NeuN stain (blue, neuronal marker). Note little to no expression of EAC3I peptide in cortex. CC = corpus callosum, Scale bar 100 µm. (E) 63× image of unstained EAC3I-EGFP expressing MSN (green = endogenous EGFP signal). Note expression in soma, dendrites and dendritic spines (arrows). Scale bar 10 µm. (F) Images of globus pallidus (GP) (left) and substantia nigra pars reticulata (SNR) (right) showing MSN axon terminals (green) and nissl stain (red). GP and SNR cell somas (red, nissl stain) are devoid of EGFP signal. CP = cerebral peduncle. Scale bars 20 µm. (G) (left) DIC image of patch pipette on a MSN in whole cell mode, (right) epifluorescence image of left panel confirming EAC3I-EGFP expression. Scale bar 20 µm. (H) Overlaid coronal images showing EAC3I-EGFP MSN axon terminal field expression in globus pallidus (left) and substania nigra pars reticulata (right) confirming indirect and direct pathway expression, respectively. Scale bar 0.5 mm.CC BY · PubMed Central
Figure 2 In vivo expression of EAC3I decreases s/mEPSC frequency in dorsal lateral striatum MSNs. (A) Representative sEPSC traces for NON EGFP (black) and EGFP (CaMKII-inhibited, green). Scale bars 50 ms and 10 pA. (B) Representative mEPSC traces for NON EGFP (black) and EGFP (CaMKII-inhibited, green). Scale bars 50 ms and 10 pA. (C) Representative sEPSC traces for NON EGFP (black) and EGFP (CaMKII-inhibited, green) MSNs from animals that were fed DOX from birth to six weeks and then removed to allow EAC3I transgene expression. Recordings were made 4–5 weeks following DOX removal at a similar age to previous. The scale bars are 50 ms and 10 pA. (D) (Left) Average sEPSC frequencies from EAC3I-containing MSNs compared to controls, (right) Cumulative probability distributions of sEPSC inter-event intervals (Wt: n = 7, p = 0.0001; tTA: n = 5, p = 0.0001; Non EGFP: n = 9, p = 0.0009; versus EGFP: n = 13). (E) (left) Average mEPSC frequency from EAC3I MSNs compared to controls, (right) cumulative probability distributions of mEPSC frequency (Wt: n = 5, p = 0.0022; tTA: n = 6, p<0.0001; Non EGFP: n = 6, p = 0.0019; versus EGFP: n = 6). (F) (Left) Average sEPSC frequencies from EAC3I-containing MSNs versus controls, (right) cumulative probability distributions of sEPSC inter-event intervals (Wt: n = 8, p = 0.99; tTA: n = 7, p = 0.99; Non EGFP: n = 8, p = 0.99; versus EGFP: n = 10). (G) (left) Average sEPSC amplitudes, (right) cumulative probability distributions of sEPSC amplitude (Wt: n = 7, p = 0.91; tTA: n = 5, p = 0.26; Non EGFP: n = 9, p = 0.99; versus EGFP: n = 13). (H) (left) Average mEPSC amplitude, (right) cumulative probability distributions of mEPSC amplitude (Wt: n = 5, p = 0.90; tTA: n = 6, p = 0.71; Non EGFP: n = 6, p = 0.96; versus EGFP: n = 6). (I) (left) Average sEPSC amplitudes, (right) cumulative probability distributions of sEPSC amplitude from animals that were fed DOX from birth to six weeks and then removed to allow EAC3I transgene expression (Wt: n = 8, p = 0.99; tTA: n = 7, p = 0.34; Non EGFP: n = 8, p = 0.99; versus EGFP: n = 10). * P<0.05; ** P<0.01; *** P<0.001; error bars represent SEM, N.S. = not significant. Note: All neurons in panels A-I are held at −70 mV during recordings.
Figure 2 In vivo expression of EAC3I decreases s/mEPSC frequency in dorsal lateral striatum MSNs. (A) Representative sEPSC traces for NON EGFP (black) and EGFP (CaMKII-inhibited, green). Scale bars 50 ms and 10 pA. (B) Representative mEPSC traces for NON EGFP (black) and EGFP (CaMKII-inhibited, green). Scale bars 50 ms and 10 pA. (C) Representative sEPSC traces for NON EGFP (black) and EGFP (CaMKII-inhibited, green) MSNs from animals that were fed DOX from birth to six weeks and then removed to allow EAC3I transgene expression. Recordings were made 4–5 weeks following DOX removal at a similar age to previous. The scale bars are 50 ms and 10 pA. (D) (Left) Average sEPSC frequencies from EAC3I-containing MSNs compared to controls, (right) Cumulative probability distributions of sEPSC inter-event intervals (Wt: n = 7, p = 0.0001; tTA: n = 5, p = 0.0001; Non EGFP: n = 9, p = 0.0009; versus EGFP: n = 13). (E) (left) Average mEPSC frequency from EAC3I MSNs compared to controls, (right) cumulative probability distributions of mEPSC frequency (Wt: n = 5, p = 0.0022; tTA: n = 6, p<0.0001; Non EGFP: n = 6, p = 0.0019; versus EGFP: n = 6). (F) (Left) Average sEPSC frequencies from EAC3I-containing MSNs versus controls, (right) cumulative probability distributions of sEPSC inter-event intervals (Wt: n = 8, p = 0.99; tTA: n = 7, p = 0.99; Non EGFP: n = 8, p = 0.99; versus EGFP: n = 10). (G) (left) Average sEPSC amplitudes, (right) cumulative probability distributions of sEPSC amplitude (Wt: n = 7, p = 0.91; tTA: n = 5, p = 0.26; Non EGFP: n = 9, p = 0.99; versus EGFP: n = 13). (H) (left) Average mEPSC amplitude, (right) cumulative probability distributions of mEPSC amplitude (Wt: n = 5, p = 0.90; tTA: n = 6, p = 0.71; Non EGFP: n = 6, p = 0.96; versus EGFP: n = 6). (I) (left) Average sEPSC amplitudes, (right) cumulative probability distributions of sEPSC amplitude from animals that were fed DOX from birth to six weeks and then removed to allow EAC3I transgene expression (Wt: n = 8, p = 0.99; tTA: n = 7, p = 0.34; Non EGFP: n = 8, p = 0.99; versus EGFP: n = 10). * P<0.05; ** P<0.01; *** P<0.001; error bars represent SEM, N.S. = not significant. Note: All neurons in panels A-I are held at −70 mV during recordings.CC BY · PubMed Central
Figure 3 Dorsal lateral striatum MSN CaMKII inhibition reduces excitatory transmission independently of changes in release probability. (A) (Upper trace, black) NON EGFP (EAC3I-lacking) MSN PPR (50 ms ISI) example trace baseline (average of 20 sweeps, 0.05 Hz). (Middle trace, black) EAC3I-lacking MSN PPR (50 ms ISI) example trace post 10 µM Baclofen wash in (average of 20 sweeps, 0.05 Hz). (Bottom trace, black) EAC3I-lacking MSN PPR (50 ms ISI) example trace 20 minutes post wash out of drug (average of 50 sweeps, 0.05 Hz). (B) Same as in (A), but for an EGFP (EAC3I-containing) MSN. (C) Average PPR recorded by paired-pulse stimulation eliciting EPSCs with two different interstimulus intervals (40 and 60 ms) for EAC3I-containing MSNs versus all controls. (Wt: n = 9; tTA: n = 6; NON EGFP: n = 9; EGFP: n = 10; 40 ISI p = 0.38, 60 ISI p = 0.27). (D) Baclofen increases the CV of EPSCs. Coefficient of variation (CV = SD/Mean) change of EPSCs from before, during and after application of baclofen for EAC3I-containing and EAC3I-lacking MSNs (NON EGFP: n = 6; EGFP: n = 5; p = 0.95). (E) Baclofen increases the PPR. PPR (50 ms ISI) for EAC3I-containing and EAC3I-lacking MSNs before, during and after application of baclofen (NON EGFP: n = 6; EGFP: n = 5; p = 0.48). (F) Baclofen decreases sEPSC frequency. Plot of normalized sEPSC frequency post 10 µM Baclofen compared to baseline for EAC3I-containing and EAC3I-lacking MSNs (NON EGFP: n = 6; EGFP: n = 5; p = 0.96). Note: All MSNs held at −70 mV during recordings.
Figure 3 Dorsal lateral striatum MSN CaMKII inhibition reduces excitatory transmission independently of changes in release probability. (A) (Upper trace, black) NON EGFP (EAC3I-lacking) MSN PPR (50 ms ISI) example trace baseline (average of 20 sweeps, 0.05 Hz). (Middle trace, black) EAC3I-lacking MSN PPR (50 ms ISI) example trace post 10 µM Baclofen wash in (average of 20 sweeps, 0.05 Hz). (Bottom trace, black) EAC3I-lacking MSN PPR (50 ms ISI) example trace 20 minutes post wash out of drug (average of 50 sweeps, 0.05 Hz). (B) Same as in (A), but for an EGFP (EAC3I-containing) MSN. (C) Average PPR recorded by paired-pulse stimulation eliciting EPSCs with two different interstimulus intervals (40 and 60 ms) for EAC3I-containing MSNs versus all controls. (Wt: n = 9; tTA: n = 6; NON EGFP: n = 9; EGFP: n = 10; 40 ISI p = 0.38, 60 ISI p = 0.27). (D) Baclofen increases the CV of EPSCs. Coefficient of variation (CV = SD/Mean) change of EPSCs from before, during and after application of baclofen for EAC3I-containing and EAC3I-lacking MSNs (NON EGFP: n = 6; EGFP: n = 5; p = 0.95). (E) Baclofen increases the PPR. PPR (50 ms ISI) for EAC3I-containing and EAC3I-lacking MSNs before, during and after application of baclofen (NON EGFP: n = 6; EGFP: n = 5; p = 0.48). (F) Baclofen decreases sEPSC frequency. Plot of normalized sEPSC frequency post 10 µM Baclofen compared to baseline for EAC3I-containing and EAC3I-lacking MSNs (NON EGFP: n = 6; EGFP: n = 5; p = 0.96). Note: All MSNs held at −70 mV during recordings.CC BY · PubMed Central
Figure 4 Dorsal lateral striatum MSN CaMKII inhibition does not alter the level of glutamate at the cleft. (A) Normalized average NMDAR-mediated EPSC Charge (AUC) measured with 0.1 Hz stimulation in the presence of 10 µM Mk-801 over time for EAC3I-containing and EAC3I-lacking MSNs. (B) The rate of NMDA-mediated EPSC decay is best fit with a single exponential decay function. The time constant (tau) in seconds was not significantly different between groups (NON EGFP: n = 6; EGFP: n = 5; p = 0.65). All neurons held at -70 mV to relieve NMDAR-dependent voltage blockade by magnesium.
Figure 4 Dorsal lateral striatum MSN CaMKII inhibition does not alter the level of glutamate at the cleft. (A) Normalized average NMDAR-mediated EPSC Charge (AUC) measured with 0.1 Hz stimulation in the presence of 10 µM Mk-801 over time for EAC3I-containing and EAC3I-lacking MSNs. (B) The rate of NMDA-mediated EPSC decay is best fit with a single exponential decay function. The time constant (tau) in seconds was not significantly different between groups (NON EGFP: n = 6; EGFP: n = 5; p = 0.65). All neurons held at -70 mV to relieve NMDAR-dependent voltage blockade by magnesium.CC BY · PubMed Central
Figure 5 CaMKII inhibition does not alter dendritic spine density, but decreases dendritic length and complexity. Rendering and quantification of a confocal image of a Lucifer yellow filled dendritic segment (80–100 µm from the cell soma) from a MSN from the dorsal lateral striatum. (A) (top) Confocal image of EAC3I-lacking MSN (NON EGFP) and the Imaris dendrite and spine model overlaid from segment above. (below) Same as above, but for an EAC3I-containg MSN segment. Scale bars 1.5 µm. Fluorescent signal (green) pertains to Lucifer yellow fill. (B) Average dendritic spine density (number of spines/10 µm) scatter plot for each neuron. NON EGFP n = 17, EGFP n = 16; p = 0.93. (C) Neuronal reconstructions of representative EAC3I-lacking (NONEGFP) and EAC3I-containing (EGFP) dorsal striatal MSNs. Scale bar 50 µm. (D) Average total dendritic length in EAC3I-lacking (black) and EAC3I-containing (green) MSNs. (E) Sholl analysis of dendritic complexity in EAC3I-lacking (black) and EAC3I-containing MSNs (green). **p<0.01, *p<0.05; error bars represent SEM.
Figure 5 CaMKII inhibition does not alter dendritic spine density, but decreases dendritic length and complexity. Rendering and quantification of a confocal image of a Lucifer yellow filled dendritic segment (80–100 µm from the cell soma) from a MSN from the dorsal lateral striatum. (A) (top) Confocal image of EAC3I-lacking MSN (NON EGFP) and the Imaris dendrite and spine model overlaid from segment above. (below) Same as above, but for an EAC3I-containg MSN segment. Scale bars 1.5 µm. Fluorescent signal (green) pertains to Lucifer yellow fill. (B) Average dendritic spine density (number of spines/10 µm) scatter plot for each neuron. NON EGFP n = 17, EGFP n = 16; p = 0.93. (C) Neuronal reconstructions of representative EAC3I-lacking (NONEGFP) and EAC3I-containing (EGFP) dorsal striatal MSNs. Scale bar 50 µm. (D) Average total dendritic length in EAC3I-lacking (black) and EAC3I-containing (green) MSNs. (E) Sholl analysis of dendritic complexity in EAC3I-lacking (black) and EAC3I-containing MSNs (green). **p<0.01, *p<0.05; error bars represent SEM.CC BY · PubMed Central
Figure 6 GluA1KO mice mimic the EAC3I mice decrease in sEPSC frequency. (A) Example traces of sEPSCs collected from dorsal lateral striatum MSNs in Wt (top) and GluA1KO (bottom). Scale bars 0.5 sec, 30 pA (Control: n = 15; GluA1KO: n = 18; p = 0.013). (B) (left) Average sEPSC frequency in GluA1KO versus controls. (right) Cumulative probability graph of inter-event interval. (C) (left) Average sEPSC amplitude in GluA1KO versus controls. (right) Cumulative probability graph of amplitude (Control: n = 15; GluA1KO: n = 18; p = 0.72). * P<0.05 ; error bars represent SEM. All MSNs were held at −70 mV.
Figure 6 GluA1KO mice mimic the EAC3I mice decrease in sEPSC frequency. (A) Example traces of sEPSCs collected from dorsal lateral striatum MSNs in Wt (top) and GluA1KO (bottom). Scale bars 0.5 sec, 30 pA (Control: n = 15; GluA1KO: n = 18; p = 0.013). (B) (left) Average sEPSC frequency in GluA1KO versus controls. (right) Cumulative probability graph of inter-event interval. (C) (left) Average sEPSC amplitude in GluA1KO versus controls. (right) Cumulative probability graph of amplitude (Control: n = 15; GluA1KO: n = 18; p = 0.72). * P<0.05 ; error bars represent SEM. All MSNs were held at −70 mV.CC BY · PubMed Central
Figure 7 CaMKII inhibition enhances MSN intrinsic excitability. (A) Traces of EAC3I-lacking (NON EGFP, black) and EAC3I-containing MSNs (EGFP, green) sEPSPs recorded at −85 mV. Scale bars 0.6 mV, 200 ms. (B) Traces of EAC3I-lacking (black) and EAC3I-containing MSNs (green) with 20 pA hyperpolarizing and depolarizing current injections (−120 pA to +100 pA above AP threshold, 20 pA steps). Scale bars 200 ms, 20 mV. (C) Average sEPSP frequency in EAC3I-containing MSNs versus controls (Wt: n = 4; tTA: n = 4; NON EGFP: n = 9; versus EGFP: n = 6; p = 0.015). (D) Average sEPSP amplitude (current clamped at −85 mV) in EAC3I-containing MSNs versus controls (Wt: n = 4; tTA: n = 4; NON EGFP: n = 9; versus EGFP: n = 6; p = 0.037). (E) Resting membrane potential (RMP) (mV) of EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p = 0.0043). (F) Input resistance of EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p = 0.0002). (G) Rheobase current injection or current injection to reach 1st AP in EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p<0.0001). (H) Firing frequency (Hz) after 4 sweeps (20 pA steps) following threshold firing in EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p = 0.0023). * P<0.05; ** P<0.01; *** P<0.001; error bars represent SEM.
Figure 7 CaMKII inhibition enhances MSN intrinsic excitability. (A) Traces of EAC3I-lacking (NON EGFP, black) and EAC3I-containing MSNs (EGFP, green) sEPSPs recorded at −85 mV. Scale bars 0.6 mV, 200 ms. (B) Traces of EAC3I-lacking (black) and EAC3I-containing MSNs (green) with 20 pA hyperpolarizing and depolarizing current injections (−120 pA to +100 pA above AP threshold, 20 pA steps). Scale bars 200 ms, 20 mV. (C) Average sEPSP frequency in EAC3I-containing MSNs versus controls (Wt: n = 4; tTA: n = 4; NON EGFP: n = 9; versus EGFP: n = 6; p = 0.015). (D) Average sEPSP amplitude (current clamped at −85 mV) in EAC3I-containing MSNs versus controls (Wt: n = 4; tTA: n = 4; NON EGFP: n = 9; versus EGFP: n = 6; p = 0.037). (E) Resting membrane potential (RMP) (mV) of EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p = 0.0043). (F) Input resistance of EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p = 0.0002). (G) Rheobase current injection or current injection to reach 1st AP in EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p<0.0001). (H) Firing frequency (Hz) after 4 sweeps (20 pA steps) following threshold firing in EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p = 0.0023). * P<0.05; ** P<0.01; *** P<0.001; error bars represent SEM.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 140 references

Research works printed but not linked: 1

  1. [106]Ciani L, Boyle KA, Dickins E, Sahores M, Anane D, et al (2011) Wnt7a signaling promotes dendritic spine growth and synaptic strength through Ca(2)(+)/Calmodulin-dependent protein kinase II. Proc Natl Acad Sci U S A 108: 10732– 10737. 21670302 PMC3127879

Cited by

See all 49

Metadata

Authors
Klug, J. R., Mathur, B. N., Kash, T. L., Wang, H.-D., Matthews, R. T., Robison, A. J., Anderson, M. E., Deutch, A. Y., Lovinger, D. M., Colbran, R. J., & Winder, D. G.
Affiliations
  • Vanderbilt University (US)
  • National Institutes of Health (US)
  • Vanderbilt University Medical Center (US)
  • University of Iowa (US)
Corresponding author
Winder, Danny G.
Venue
PLoS ONE
Published
2012-09-21
Volume
7
Issue
9
Pages
e45323
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1972992241
Cited by
49
References
140
Citations by year
2026: 3 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 5 · 2015: 4 · 2014: 6 · 2013: 6
FWCI
2.11
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Vanderbilt University
  • Fondation Leducq
  • National Institutes of Health (NIH-R01, AA019455)
  • National Institute on Alcohol Abuse and Alcoholism (R01AA019455)
  • National Heart, Lung, and Blood Institute (R01 HL70250, R01HL62494, R01HL079031, R01HL113001, R01HL070250, R01HL062494)
  • National Institute of Mental Health (T32MH064913, R01MH063232)
  • National Institute on Drug Abuse (R01DA019112)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
CaMKII, dorsal striatum, medium spiny neurons, CaMKII inhibition, excitatory synaptic transmission, intrinsic excitability, GluR1, AMPA receptors, spontaneous excitatory postsynaptic currents, dopamine signaling, transgenic mouse model, Parkinson's disease, addiction
MeSH terms
Animals, Corpus Striatum, Female, Male, Mice, Transgenic, Synaptic Transmission, Neurons, Peptides, Receptors, AMPA, Excitatory Postsynaptic Potentials, Mice, Calcium-Calmodulin-Dependent Protein Kinase Type 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic Inhibition of CaMKII in Dorsal Striatal Medium Spiny Neurons Reduces Functional Excitatory Synapses and Enhances Intrinsic Excitability. https://app.cochat.ai/papers/10.1371/journal.pone.0045323
The paper
Klug, J. R., Mathur, B. N., Kash, T. L., Wang, H.-D., Matthews, R. T., Robison, A. J., Anderson, M. E., Deutch, A. Y., Lovinger, D. M., Colbran, R. J., & Winder, D. G. (2012). Genetic Inhibition of CaMKII in Dorsal Striatal Medium Spiny Neurons Reduces Functional Excitatory Synapses and Enhances Intrinsic Excitability. PLoS ONE. https://doi.org/10.1371/journal.pone.0045323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.